Bluejay Diagnostics (BJDX) ties director’s options to FDA device clearance
Rhea-AI Filing Summary
Bluejay Diagnostics, Inc. (BJDX) reported that director Wurth Douglas Clark received a grant of stock options for 100,000 shares of common stock. The options have an exercise price of $2.075 per share, expire on August 17, 2031, and are currently out-of-the-money. They vest on the first anniversary of the grant date and cannot be exercised unless and until the U.S. Food and Drug Administration grants clearance or approval of Bluejay’s Symphony IL-6 point-of-care testing device.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Wurth Douglas Clark
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) F1 | 100,000 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (Right to Buy) — 100,000 shares (Direct)
Footnotes (1)
- F1. Represents out-of-the-money stock options that vest and become exercisable for $2.075 per share on the first anniversary of the grant date, provided, however, that the options shall not be exercisable unless and until the U.S. Food and Drug Administration shall have granted clearance or approval of the issuer's Symphony IL-6 point-of-care testing device.
Key Figures
Options granted: 100000 shares
Exercise price: $2.075 per share
Underlying shares: 100000 shares
+1 more
4 metrics
Options granted
100000 shares
Stock options for common stock granted to director Wurth Douglas Clark
Exercise price
$2.075 per share
Conversion or exercise price of the granted stock options
Underlying shares
100000 shares
Number of common shares underlying the granted stock options
Option expiration date
2031-08-17
Expiration date of the granted stock options
Key Terms
out-of-the-money, vest and become exercisable, point-of-care testing device
3 terms
out-of-the-money financial
"Represents out-of-the-money stock options that vest and become exercisable"
vest and become exercisable financial
"stock options that vest and become exercisable for $2.075 per share"
point-of-care testing device medical
"approval of the issuer's Symphony IL-6 point-of-care testing device"
FAQ
What insider transaction did BJDX report for Wurth Douglas Clark?
Bluejay Diagnostics (BJDX) reported that director Wurth Douglas Clark received a grant of 100,000 stock options. These options are for common stock and represent a compensation-related acquisition rather than an open-market purchase or sale.
What is the exercise price of the new BJDX stock options granted to Wurth Douglas Clark?
The stock options granted to Wurth Douglas Clark have an exercise price of $2.075 per share. They are described as out-of-the-money options that become exercisable only after vesting and upon specified FDA clearance or approval conditions.
When do Wurth Douglas Clark’s BJDX options vest and become exercisable?
The options vest and become exercisable on the first anniversary of the grant date. However, they are additionally conditioned on the U.S. FDA granting clearance or approval of Bluejay’s Symphony IL-6 point-of-care testing device.
What regulatory condition affects exercisability of Wurth Douglas Clark’s BJDX options?
The options are not exercisable unless and until the U.S. Food and Drug Administration grants clearance or approval of Bluejay Diagnostics’ Symphony IL-6 point-of-care testing device, adding a regulatory milestone condition beyond standard vesting.
When do the BJDX stock options granted to Wurth Douglas Clark expire?
The stock options granted to Wurth Douglas Clark expire on August 17, 2031. If vesting and the FDA clearance or approval condition are not satisfied before that date, any unexercised portion of the option would remain unexercisable through expiration.
AI-generated analysis. How Rhea-AI works. Not financial advice.
